International review of neurobiology, Год журнала: 2023, Номер unknown, С. 1 - 58
Опубликована: Дек. 1, 2023
Язык: Английский
Translational Neurodegeneration, Год журнала: 2023, Номер 12(1)
Опубликована: Фев. 13, 2023
Abstract Disruptions of circadian rhythms and sleep cycles are common among neurodegenerative diseases can occur at multiple levels. Accumulating evidence reveals a bidirectional relationship between disruptions diseases. Circadian disruption disorders aggravate neurodegeneration in turn disrupt sleep. Importantly, various increase the risk Thus, harnessing biology findings from preclinical translational research is importance for reducing improving symptoms quality life individuals with via approaches that normalize context precision medicine. In this review, we discuss implications by summarizing both human animal studies, focusing on links prevalent forms neurodegeneration. These provide valuable insights into pathogenesis suggest promising role circadian-based interventions.
Язык: Английский
Процитировано
70
Frontiers in Psychiatry, Год журнала: 2021, Номер 12
Опубликована: Июнь 10, 2021
Introduction: Insomnia and circadian rhythm disorders, such as the delayed sleep phase syndrome, are frequent in psychiatric disorders their evaluation management early stages should be a priority. The aim of this paper was to express recommendations on use exogenous melatonin, which exhibits both chronobiotic sleep-promoting actions, for treatment these disturbances disorders. Methods: To aim, we conducted systematic review according PRISMA melatonin insomnia neuropsychiatry. We expressed clinical practice each disorder using RAND/UCLA appropriateness method. Results: selected 41 studies, included mood schizophrenia, substance attention deficit hyperactivity autism spectrum neurocognitive delirium; no studies were found anxiety eating Conclusion: administration prolonged release at 2–10 mg, 1–2 h before bedtime, might used symptoms or comorbid adults with during sedative-hypnotics discontinuation. Immediate <1 mg useful neuropsychiatric
Язык: Английский
Процитировано
62
Journal of Parkinson s Disease, Год журнала: 2022, Номер 12(7), С. 2029 - 2058
Опубликована: Авг. 2, 2022
Parkinson's disease (PD) is defined by its motor symptoms rigidity, tremor, and akinesia. However, non-motor symptoms, particularly autonomic disorders sleep disturbances, occur frequently in PD causing equivalent or even greater discomfort than effectively decreasing quality of life patients caregivers. Most common disturbances are insomnia, disordered breathing, excessive daytime sleepiness, REM behavior disorder, sleep-related movement such as restless legs syndrome. Despite their high prevalence, therapeutic options the in- outpatient setting limited, partly due to lack scientific evidence. The importance neurodegenerative diseases has been further emphasized recent evidence indicating a bidirectional relationship between neurodegeneration sleep. A more profound insight into underlying pathophysiological mechanisms intertwining might lead unique individually tailored modifying neuroprotective long run. Therefore, current concerning management will be discussed with aim providing substantiated scaffolding for clinical decisions long-term therapy.
Язык: Английский
Процитировано
42
Practical Neurology, Год журнала: 2023, Номер 23(3), С. 208 - 221
Опубликована: Март 16, 2023
This is a practical guide to diagnosing and managing multiple system atrophy (MSA). We explain the newly published Movement Disorders Society Consensus Diagnostic Criteria, which include new ‘Clinically Established MSA’ ‘Possible Prodromal categories, hopefully reducing time diagnosis. then highlight key clinical features of MSA aid list mimics with suggested methods differentiation from MSA. Lastly, we discuss symptom management in people living MSA, including balancing side effects, ultimate aim improving quality life.
Язык: Английский
Процитировано
38
Neurology and Therapy, Год журнала: 2024, Номер 13(3), С. 885 - 906
Опубликована: Май 8, 2024
This pragmatic review synthesises the current understanding of prodromal dementia with Lewy bodies (pDLB) and Alzheimer's disease (pAD), including clinical presentations, neuropsychological profiles, neuropsychiatric symptoms, biomarkers, indications for management. The core features (DLB)—parkinsonism, complex visual hallucinations, cognitive fluctuations, REM sleep behaviour disorder are common symptoms. Supportive pDLB include severe neuroleptic sensitivity, as well autonomic profile in mild impairment attributable to body pathology (MCI-LB) tends visuospatial skills executive functioning, distinguishing it from MCI due AD, which typically presents memory. may present impairment, psychiatric and/or recurrent episodes delirium, indicating that is not necessarily synonymous MCI-LB. Imaging, fluid other biomarkers play a crucial role differentiating pAD. MCI-LB criteria recognise low dopamine transporter uptake using positron emission tomography or single photon computed (SPECT), loss atonia on polysomnography, sympathetic cardiac denervation meta-iodobenzylguanidine SPECT indicative slowing dominant frequency EEG among others supportive biomarkers. also highlights emergence skin-based There little research evidence treatment pDLB, but pharmacological non-pharmacological treatments DLB be discussed patients. Non-pharmacological interventions such diet, exercise, stimulation provide benefit, while evaluation management contributing factors like medications disturbances vital. need expand across diverse patient populations address existing disparities trial participation. In conclusion, an early accurate diagnosis pAD opportunity tailored interventions, improved healthcare outcomes, enhanced quality life patients care partners.
Язык: Английский
Процитировано
11
Journal of Neurology, Год журнала: 2025, Номер 272(1)
Опубликована: Янв. 1, 2025
Non-motor symptoms frequently develop throughout the disease course of Parkinson's (PD), and pose affected individuals at risk complications, more rapid progression poorer quality life. Addressing such symptom burden, 2023 revised "Parkinson's disease" guideline German Society Neurology aimed providing evidence-based recommendations for managing PD non-motor symptoms, including autonomic failure, pain sleep disturbances.
Язык: Английский
Процитировано
1
Current Neuropharmacology, Год журнала: 2021, Номер 19(12), С. 2233 - 2249
Опубликована: Май 18, 2021
Sleep disorders are one of the most common non-motor symptoms in Parkinson's disease (PD). It can cause a notable decrease quality life and functioning PD patients, as well place huge burden on both patients caregivers. The cited sleep included insomnia, restless legs syndrome (RLS), rapid eye movement (REM), behavior (RBD), excessive daytime sleepiness (EDS) disordered breathing (SDB), which appear alone or several at same time. In this review, we listed recommended pharmacological treatments for PD, discussed dosages, benefits side effects relative drugs. We also non-pharmacological to improve quality, including hygiene education, exercise, deep brain stimulation, cognitive therapy complementary therapies. tried find proper interventions different types while minimizing effects.
Язык: Английский
Процитировано
37
SLEEP, Год журнала: 2023, Номер 46(8)
Опубликована: Апрель 13, 2023
Abstract Study Objectives Symptomatic therapies for rapid-eye-movement (REM) sleep behavior disorder (RBD) are limited. Sodium oxybate (SXB), a gamma-aminobutyric acid (GABA)-B agonist, could be effective but has not been evaluated against placebo. Methods This double-blind, parallel-group, randomized, placebo-controlled trial in 24 participants was conducted at the Stanford Sleep Center. Patients were adults with definite iRBD or Parkinson’s disease and probable RBD (PD-RBD), persistence of ≥ 2 weekly episodes despite standard therapy. randomized 1:1 to receive SXB during 4-week titration followed by stable dosing period. Primary outcome number monthly according diary filled patients partners. Secondary outcomes severity, severe episodes, objective activity on video polysomnography. Results Twelve 12 PD-RBD participated (mean 65.8 years), 22 (n = 10 SXB, placebo) completed study. Although no significant between-group difference found, showed reduction 23.1 (95% CI −36.0, −10.2; p 0.001) versus 10.5 placebo CI, −22.6, 1.6; 0.087). Improvement from baseline similarly observed overall severity burden (each episode weighted severity), per video-polysomnography. Two receiving withdrew due anxiety dizziness. The majority adverse events otherwise resolved dose adjustment. Conclusion reduce symptoms; however, response inconsistent large effect across patient-reported outcomes. Larger studies using endpoints needed. Clinical Trial Treatment REM Behavior Disorder With Oxybate https://clinicaltrials.gov/ct2/show/NCT04006925 ClinicalTrials.gov identifier: NCT04006925
Язык: Английский
Процитировано
13
Nature and Science of Sleep, Год журнала: 2023, Номер Volume 15, С. 333 - 352
Опубликована: Май 1, 2023
Abstract: Rapid eye movement (REM) sleep behavior disorder (RBD) is the result of loss physiological inhibition muscle tone during REM sleep, characterized by dream-enacting and widely recognized as a prodromal manifestation alpha-synucleinopathies. Indeed, patients with isolated RBD (iRBD) have an extremely high estimated risk to develop neurodegenerative disease after long follow up. Nevertheless, in comparison PD without (PDnoRBD), occurrence context (PDRBD) seems identify unique, more malignant phenotype, severe burden terms both motor non-motor symptoms increased for cognitive decline. However, while some medications (eg, melatonin, clonazepam, etc.) non-pharmacological options been found therapeutic benefits on there no available treatment able modify course or, at least, slow down process underlying phenoconversion. In this scenario, phase may allow early window and, therefore, identification multimodal biomarkers onset progression becoming increasingly crucial. To date, several clinical (motor, cognitive, olfactory, visual, autonomic features) neurophysiological, neuroimaging, biological (biofluids or tissue biopsy), genetic identified proposed, also combination, possible diagnostic prognostic markers, along potential role them outcome measures index response. review, we provide insight into present knowledge existing future iRBD highlight difference PDRBD PDnoRBD, including currently options. Keywords: Parkinson's disease, disorder, synucleinopathy, biomarkers, neurodegeneration
Язык: Английский
Процитировано
12
Nature and Science of Sleep, Год журнала: 2022, Номер Volume 14, С. 1843 - 1855
Опубликована: Окт. 1, 2022
Abstract: Aging is accompanied by circadian changes, including disruptive alterations in the sleep/wake cycle, as well beginning of low-degree inflammation ("inflammaging"), a scenario that leads to several chronic illnesses, cancer, and metabolic, cardiovascular, neurological dysfunctions. As result, any effective approach healthy aging must consider both correction disturbance control low-grade inflammation. One most important prerequisites for preservation robust rhythmicity (particularly cycle). Sleep disrupts various activities central nervous system, waste molecule elimination. Melatonin chemical with extraordinary phylogenetic conservation found all known aerobic creatures whose alteration plays an role sleep changes aging. Every day, late afternoon/nocturnal surge pineal melatonin helps synchronize pacemaker hypothalamic suprachiasmatic nuclei (SCN) plethora peripheral cellular clocks. example endogenous chronobiotic substance can influence timing amplitude rhythms. Moreover, also excellent anti-inflammatory agent, buffering free radicals, down-regulating proinflammatory cytokines, reducing insulin resistance, among other things. We present scientific clinical evidence safe drug treating disturbances elderly. Keywords: melatonin, sleep, elderly, safety, neurodegeneration
Язык: Английский
Процитировано
17